Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates

Fakhim, H and Ahangarkani, F and F. Meis, J and Badali, H and Haghani, I and Javidnia, J and Ilkit, M and Abastabar, M and Taheri Rizi, Z (2020) Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates. Mycopathologia. pp. 1-9.

Preview

Text 1791.pdf Download (224kB) | Preview

Abstract

Management of superficial aspergillosis is a major challenge owing to the frequent relapses and treatment failure, which may pose a potential risk, thereby gradually developing resistant species. There- fore, necessitating the development of new antifungals with higher potency should be considered as alterna- tive strategies for efficient management of infections. We aimed to investigate the susceptibility of Aspergillus isolates toward a novel triazole, efina- conazole, in comparison with various classes of antifungal drugs. Antifungal susceptibility testing was performed according to the Clinical and Labora- tory Standards Institute M38-A2 guidelines. Efina- conazole exhibited poor activity against mutant A. fumigatus strains, A. niger sensu stricto, and A. tubingensis with GM MIC values of 3.62, 1.62, and 2 lg/ml, respectively; however, surprisingly, it effi- ciently inhibited the growth of A. terreus sensu stricto,

Actions (login required)

View Item